Onco Wiki - Régimen

cinacalcet para hipercalcemia de carcinoma paratiroideo

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.

Fuente YAML: registro completo

Notas

STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode- exempted draft content). Cinacalcet controls PTH-driven hypercalcemia in unresectable, recurrent, or metastatic parathyroid carcinoma; it has no direct antitumor effect. Re-resection of accessible disease, where surgically feasible, remains the preferred disease-directed intervention alongside this regimen in the recurrent/metastatic setting (see IND-PARATHYROID-CARCINOMA-2L-CINACALCET) — not encoded as a regimen component because surgical feasibility is patient/anatomy-specific, not a fixed pharmacologic step. Bisphosphonates (DRUG-ZOLEDRONATE) or denosumab (DRUG-DENOSUMAB) are complementary options for skeletal-related-event prevention in bone-metastatic disease and for hypercalcemia refractory to cinacalcet alone — not bundled into this regimen because they act on a distinct mechanism (osteoclast-mediated bone turnover vs. PTH secretion) and no fixed combination schedule is established in guidelines; use per concurrent clinical need alongside this regimen.

Utilizado por

Enfermedad

• DIS-PARATHYROID-CARCINOMA - Carcinoma paratiroideo

Indicación

• IND-PARATHYROID-CARCINOMA-2L-CINACALCET - IND-PARATHYROID-CARCINOMA-2L-CINACALCET